FNCHQ (Finch Therapeutics Group) Insider Ownership: 6.84 % (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FNCHQ Finch Therapeutics Group Inc FNCHQ
12 GF Score
Price $10.20
View Full Analysis

What is Finch Therapeutics Group Insider Ownership?

Finch Therapeutics Group FNCHQ 12 Insider Ownership is 6.84 % as of Aug. 19, 2026. GuruFocus rates FNCHQ with a GF Score™ of 12/100.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Finch Therapeutics Group's insider ownership is 6.84%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Finch Therapeutics Group's Institutional Ownership is 1.32%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Finch Therapeutics Group's Float Percentage Of Total Shares Outstanding is 43.17%.

Finch Therapeutics Group Insider Ownership Historical Data

* Premium members only.

The historical data trend for Finch Therapeutics Group's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Finch Therapeutics Group Insider Ownership Chart

Finch Therapeutics Group Historical Data

The historical data trend for Finch Therapeutics Group can be seen below:

2022-08-31 2022-09-30 2022-10-31 2022-11-30 2022-12-31 2023-01-31 2023-02-28 2023-03-31 2023-04-30 2023-05-31
Insider Ownership 6.93 6.93 6.91 6.88 6.88 6.88 6.87 6.84 6.84 6.84
FNCHQ
12GF Score
Finch Therapeutics Group Inc FNCHQ
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Finch Therapeutics Group Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 6.84 % mean?
Finch Therapeutics Group (FNCHQ) has a Insider Ownership of 6.84 % as of Aug. 19, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Finch Therapeutics Group and its competitors.
Is Finch Therapeutics Group's Insider Ownership too high?
Finch Therapeutics Group's current Insider Ownership is 6.84 %. Overall, Finch Therapeutics Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Finch Therapeutics Group's Insider Ownership compare to CRIS and LSB?
Finch Therapeutics Group's Insider Ownership of 6.84 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Finch Therapeutics Group and its competitors. Finch Therapeutics Group's current Insider Ownership is 6.84 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Finch Therapeutics Group stock overvalued right now?
Finch Therapeutics Group (FNCHQ) has a current Insider Ownership of 6.84 %. The current Insider Ownership is 6.84 %. Finch Therapeutics Group's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Finch Therapeutics Group (FNCHQ), the current Insider Ownership is 6.84 % as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Finch Therapeutics Group Business Description

Address 75 State Street, Suite 100, Boston, MA, USA, 02109
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
12GF Score

Get the complete analysis for FNCHQ

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.20
Price